Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-07-02T20:58:07.087Z Has data issue: false hasContentIssue false

The impact of biotechnology and molecular biology on the pharmaceutical industry

Published online by Cambridge University Press:  05 December 2011

A. N. Hobden
Affiliation:
Biotechnology, Glaxo Group Research Ltd, Greenford UB6 0HE, U.K.
T. J. R. Harris
Affiliation:
Biotechnology, Glaxo Group Research Ltd, Greenford UB6 0HE, U.K.
Get access

Synopsis:

Biotechnology had its initial impact on the pharmaceutical industry well before the perceived time. The use of fermentation technology to produce antibiotics was a cornerstone for the development of the industry. This event was both before cloning (BC) and before DNA (rather than after DNA – AD). Even now the antibiotic market, which is worth over 10 billion U.S. dollars a year, is the most valuable segment of the total market, (c.200 billion dollars per year). Nevertheless the impact of biotechnology in drug discovery was until recently perceived solely to be the use of recombinant DNA techniques to produce therapeutic proteins and modified versions of them by protein engineering.

There are several other places where genetic engineering is influencing drug discovery. The expression of recombinant proteins in surrogate systems (e.g. in E. coli, yeast or via baculovirus infection or in mammalian cells) provides materials for structure determination (e.g. HIV protease) and structure/function studies (e.g. various receptors). Recombinant DNA techniques are influencing assay technology by allowing access to proteins in sufficient quantity for high throughput screening.

In addition, screening organisms can be constructed where a particular protein function can be measured in a microorganism by complementation or via reporter gene expression.

Transgenic animals also illustrate the power of the technology for drug discovery. Not only will transgenic rats and mice be used as models of disease but also for efficacy and toxicological profiling. What is learned in transgenic rodents may well set the scene for somatic cell gene therapy in humans.

Type
Research Article
Copyright
Copyright © Royal Society of Edinburgh 1992

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baum, E. Z., Bebernitz, G. A., & Glutzman, Y., 1990. Isolation and characterization of sulfhydryl and disulfide peptides of human apolipoprotein B-100. Proceedings of the National Academy of Sciences, U.S.A. 87, 5523–77.Google Scholar
Dohlmann, H. G., Thorner, J., Caron, M. G., & Lefkowitz, R. J., 1990. Model systems for the study of seven-transmembrane segment receptors. Annual Review of Biochemistry 60, 653–88.CrossRefGoogle Scholar
King, K., Dohlman, H. G., Thorner, J., Caron, M. G., & Lefkowitz, R. J., 1990. Control of yeast mating signal transduction by a mammalian β2-adrenergic receptor and Gsα subunit. Science 1990 250, 121–3.Google Scholar
McHale, M. M., Cieslinski, L. B., Eng, W-K., Johnson, R. K., Tosphy, J. J., & Livi, G. P., 1991. Expression of human recombinant cAMP phosphodiesterase isozyme IV reverses growth arrest phenotypes in phosphodiesterase-deficient yeast. Molecular Pharmacology 39, 109–13.Google Scholar
Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., & Leder, P., 1988. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105–15.CrossRefGoogle ScholarPubMed